Wedbush: The AI market is in the third year of a decade-long building cycle

Telomir Pharmaceuticals Inc's latest research shows that the company has achieved extensive tumor cell death rates in human triple-negative breast cancer experimental models.

Medical technology company Masimo recently disclosed that, in its first full fiscal year following the completion of a major transaction, its adjusted diluted earnings per common share are expected to see a significant increase.

Contango Ore, Inc. (Contango) recently disclosed the latest operational updates to the market regarding its core asset—the Johnson Tract critical metals project, the development progress of the Manh Choh mine, and related hedging settlement arrangements.

According to the latest filing with the U.S. Securities and Exchange Commission (SEC), NEUROONE MEDICAL TECH has made explicit forecasts regarding its future performance.